Medical Countermeasures and Military Health: What Drug Developers Need to Know Before MHSRS
Medical countermeasures have long played an important role in protecting service members and supporting national preparedness. Today, a combination of evolving global security concerns, increased government investment, and advances in biomedical science is creating new opportunities for sponsors to contribute to this critical area of military health.
As the Military Health System Research Symposium (MHSRS) approaches, many life science and drug development companies are evaluating how to align with emerging military health priorities.
For many organizations, the most compelling opportunity lies in an unexpected place: identifying how an existing therapy, platform technology, or development program may address a military health need.
Why Military Health Is Receiving Increased Attention
Medical countermeasures encompass a broad range of products designed to prevent, mitigate, or treat the effects of chemical, biological, radiological, nuclear, infectious disease, and trauma-related threats. These programs support military readiness while also strengthening preparedness for public health emergencies.
Growing global tension and infectious disease outbreaks have shifted federal focus toward investing in military health research and development, and this environment has created significant opportunities for organizations with therapies already approved or under development for commercial indications. Rather than starting with a completely new molecule, many sponsors are evaluating whether an existing product could address a military health challenge.
This approach is especially relevant for treatments that target biological processes associated with injury, inflammation, wound healing, fibrosis, infection, or hematologic recovery. In many cases, the same physiological pathways involved in civilian diseases or injuries may also be relevant to conditions associated with military exposures.
The Growing Opportunity in Drug Repurposing
One of the most active areas within medical countermeasure development involves repurposing therapies that already exist.
Sponsors with products developed for traditional indications should ask an important question: could this therapy also benefit patients exposed to a military or public health threat?
The answer is tied to the concept of treating the body’s symptomatic response than focusing exclusively on the source of the injury or ailment. Different threats can produce similar physiological effects, creating opportunities to apply existing therapies in new settings.
For example, treatments developed for wound healing, inflammatory conditions, burns, or hematologic recovery may have potential applications in areas such as radiation injury, chemical exposure, infectious disease response, or trauma care. Existing products with established safety profiles may offer a strong foundation for further development when supported by appropriate scientific and regulatory evidence.
Understanding the FDA Animal Rule
Organizations entering the medical countermeasure space quickly encounter one of the field’s most important regulatory frameworks: the FDA Animal Rule.
Unlike traditional therapeutic development programs, medical countermeasures cannot be evaluated through human efficacy studies because exposing healthy volunteers to a lethal pathogen, radiation source, or chemical threat would be unethical. As a result, efficacy must be demonstrated through carefully designed animal studies.
The FDA Animal Rule provides the pathway for this process.
As described in the article “Animal Model Considerations for Medical Countermeasure Development for Radiation and Sulfur Mustard Exposures,” successful countermeasure development depends on selecting animal models that closely reproduce human disease processes and generate data that can reliably predict clinical benefit. Model selection, translational endpoints, biological variability, and study design all play critical roles in generating evidence that supports regulatory decision-making.
Animal Rule programs require a rigorous scientific foundation. Sponsors must understand the mechanism of action of their product, establish clinically meaningful endpoints, and demonstrate how efficacy observed in animals translates to human benefit.
These studies are far more sophisticated than simple proof-of-concept experiments. They are designed to serve as a surrogate for human efficacy trials and demand careful planning from the earliest stages of development.
Challenges and Opportunities in Countermeasure Development
The scientific and regulatory requirements associated with medical countermeasure programs create both challenges and opportunities for sponsors.
One common challenge is underestimating the complexity of Animal Rule development. Many organizations enter the space expecting a straightforward extension of an existing program, only to discover that specialized animal models, translational endpoints, and regulatory considerations require a dedicated development strategy.
Another challenge involves model selection. Medical countermeasures often address highly specialized injuries or exposures that require sophisticated preclinical systems. Large-animal models, nonhuman primates, rabbits, ferrets, and other species may be needed depending on the threat being studied and the mechanism being evaluated.
At the same time, these programs offer substantial opportunities. Sponsors with a strong understanding of their product’s mechanism of action can often identify connections between existing therapeutic applications and military health needs. Organizations that engage experienced scientific and regulatory partners early in development are well positioned to design studies that generate meaningful, decision-quality data.
Success in this field depends on understanding both the science and the regulatory framework. The strongest programs typically begin with a clear translational strategy that connects the biology of the threat, the mechanism of the therapy, and the evidence required for regulatory approval.
Looking Ahead to MHSRS
MHSRS continues to serve as one of the most important forums for advancing collaboration across the military health community. The meeting brings together government agencies, military researchers, industry sponsors, and scientific experts who are working to address some of the most complex health challenges facing service members and civilian populations.
For biotechnology and pharmaceutical companies, the conference provides an opportunity to evaluate how existing products, platform technologies, and development programs may align with emerging military health priorities.
Organizations that understand the unique requirements of medical countermeasure development, including the FDA Animal Rule, are well positioned to pursue new funding opportunities, strategic partnerships, and innovative pathways for product development.
Lovelace Biomedical has supported military health and medical countermeasure programs for more than 60 years and continues to work with sponsors developing therapies for critical areas of need. If you will be attending MHSRS, we welcome the opportunity to discuss your development strategy, evaluate potential military health applications for your product, and explore pathways for advancing medical countermeasure programs.
Schedule a meeting with our team during MHSRS to learn how specialized preclinical research, translational expertise, and Animal Rule experience can help support your military health development goals.